AMRI is showcasing its comprehensive portfolio of active pharmaceutical ingredients (APIs) and capabilities at CPhI Worldwide this week. AMRI’s July 2016 acquisition of Euticals positions AMRI as one of the largest independent developers and suppliers of API to the pharmaceutical industry and provides the company with an established presence in key European markets.

AMRI provides a broad range of complex API to the life sciences industry, including sterile and high potency APIs, steroids, generics, monobactams, boronic acids and controlled substances.

“As AMRI celebrates its 25th anniversary, CPhI presents the perfect opportunity to reveal AMRI and Euticals as one combined company that can offer a greatly expanded portfolio of market-leading APIs and world-class capabilities in niche and high-barrier-to-entry technologies,” said Margalit Fine, executive vice president of API, AMRI. “In addition to an extensive API portfolio, we can now offer our customers U.S. and European-based chemical development expertise for early stage compounds, custom synthesis and contract manufacturing expertise, as well as extensive technology expertise in specialty areas such as hydrogenation, fermentation, photocatalytic chemistry, bio transformation, industrial chromatography, flow chemistry and spray drying.”
AMRI Expands Portfolio